Compare T-Rex 2X Inverse MSTR Daily Target ETF (MSTZ) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
T-Rex 2X Inverse MSTR Daily Target ETF vs Novo Nordisk A/S — how do they compare? T-Rex 2X Inverse MSTR Daily Target ETF trades at $2.62 (market cap $94.46M), while Novo Nordisk A/S trades at $38.64 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 1750.1× T-Rex 2X Inverse MSTR Daily Target ETF's market cap, and Novo Nordisk A/S pays a 4.71% dividend while T-Rex 2X Inverse MSTR Daily Target ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold T-Rex 2X Inverse MSTR Daily Target ETF for 8 Days and Novo Nordisk A/S for 116 Days on average.
| MSTZ | NVO | |
|---|---|---|
Market Cap | $94.46M | $165.31B |
Volume | 104,717,733 | 11,432,838 |
Sector | Leveraged / Inverse | Health |
52-Week High | $27.92 | $63.98 |
52-Week Low | $2.29 | $35.29 |
Typical Hold Time | 8 Days | 116 Days |
Enterprise Value | — | $179.56B |
Dividend Yield | — | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSTZ trades at $2.73, up 2.63% today, but technical indicators show a bearish trend with moving averages signaling caution. The stock lacks available fundamental data for key valuation and profitability metrics, making financial health assessment challenging. Recent ETF performance coverage highlights market volatility but provides no direct company-specific news.
The outlook is clouded by missing financials and bearish technicals. Investment opportunity hinges on future earnings visibility and competitive positioning. Key risks include potential weak fundamentals, market volatility, and lack of analyst coverage, requiring careful due diligence before consideration.
Novo Nordisk (NVO) trades at $38.18, down 0.21% with a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (35.35% net margin, 59.82% ROE). Recent news highlights pipeline developments including Wegovy pill data and a $4 billion licensing deal, though the FDA extended review of its hemophilia drug. Cash flow remains positive at $10.81B for 2025, supporting dividend payments.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 17% upside to the $44.67 consensus target. However, competitive pressure from Eli Lilly's obesity drug pipeline and regulatory delays pose near-term risks. Analyst sentiment is bullish (59% buy ratings), but investors should monitor Q3 2026 earnings against the 0.753 EPS expectation for confirmation of growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About T-Rex 2X Inverse MSTR Daily Target ETF
MSTZ is a leveraged ETF that seeks daily investment results corresponding to 200% of the inverse (opposite) of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bearish position on MSTR, a company known for its large Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from its stated daily objective.
Read more on MSTZ →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
